Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pleural Disorders: Types and Brief Description

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same author

Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies.

Thorax·2026

Same author

Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

[Malignant mesothelioma].

Arnaud Scherpereel¹

¹Service de pneumologie et oncologie thoracique, hôpital Calmette, CHRU de Lille, Faculté de médecine Henri-Warembourg, université de Lille-II, unité Inserm 774, Lille. a-scherpereel@chru-lille.fr

La Revue Du Praticien

|August 1, 2009

Summary

This summary is machine-generated.

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer linked to asbestos exposure. Recent advancements in diagnosis and multimodal treatments are improving patient management and outcomes.

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Experiment Videos

Last Updated: Jun 21, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Area of Science:

Oncology
Pulmonology
Environmental Health

Context:

Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic malignancy.
Increasing incidence is linked to asbestos fiber exposure, the primary etiological factor.
Growing interest in MPM is driven by recent diagnostic and therapeutic advancements.

Purpose:

To summarize current understanding and management of malignant pleural mesothelioma.
To highlight recent improvements in diagnosis and treatment strategies.
To provide an overview of updated expert guidelines for MPM management.

Summary:

MPM is an aggressive tumor with rising incidence due to asbestos exposure.
Advances include new cytotoxic drugs and multimodal treatments (chemotherapy, surgery, radiotherapy).
Management is guided by updated expert conference guidelines from the European Respiratory Society.

Impact:

Improved diagnostic capabilities for MPM.
Enhanced therapeutic options, including multimodal approaches.
Standardized clinical management based on current expert guidelines.